financing

The company will use the funds to expand its clinical genomic testing efforts into additional towns and cities in India, and accelerate its drug discovery programs.

The firm said the BARDA funding will support scale-up of a molecular test to facilitate management of the coronavirus pandemic cycle.

As part of the placement, the Singapore-based firm has issued almost 17.9 million new ordinary shares at an issue price of $.175 per share. 

The firm will use the funding to expand access to its microbial cell-free DNA technology to help doctors diagnose infectious disease.

The company plans to use the funds to fuel its diagnostic development work, focused on predicting drug response in various autoimmune diseases.

The company said the funding will support international expansion of its FebriDx rapid point-of-care test and its US clinical trial.

The Stockholm-based company said it will use the funds to develop its metabolism-based liquid biopsy platform.

The financing round comes as Color expands its partnerships with healthcare systems and builds out a national genetic counseling resource for NIH's All of Us program.